Detalhe da pesquisa
1.
Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.
Br J Haematol
; 175(5): 884-891, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27682187
2.
Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study.
Eur J Haematol
; 97(3): 303-9, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26710662
3.
Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.
Am J Hematol
; 91(6): 575-80, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26955792
4.
Bone healing in multiple myeloma: a prospective evaluation of the impact of first-line anti-myeloma treatment.
Haematologica
; 101(10): e419-e422, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27365490
5.
Baseline bone involvement in multiple myeloma - a prospective comparison of conventional X-ray, low-dose computed tomography, and 18flourodeoxyglucose positron emission tomography in previously untreated patients.
Haematologica
; 101(10): e415-e418, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27390357
6.
Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population.
PLoS One
; 12(12): e0188988, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29216227
7.
Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma.
Clin Hematol Int
; 2(1): 35-39, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34595441